Publications by authors named "David Shifteh"

Claim this Profile
A
A Further Case for Targeting PRMT5 and the ERK1/2 and PI3K Pathways in CRC.
Mark Spivak, Moshe Pahmer, Dorna Delrahimnia, Tzuriel Sapir, David Shifteh

Int J Mol Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer.
Ethan Abizadeh, Eli Berglas, Aaron Abizadeh, Julia Glatman, Aaron B Lavi, David Shifteh

Int J Mol Sci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRMT5 Inhibition as a Potential Strategy for KRAS Mutant CRC: Downstream Mediators of the PRMT5-KRAS Crosstalk.
Mark Spivak, Moshe Pahmer, Dorna Delrahimnia, Tzuriel Sapir, David Shifteh

Curr Issues Mol Biol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and Emerging Therapies for Targeting Protein Arginine Methyltransferases (PRMTs) in Cancer.
Adriana Kaganovski, Bayle Smith-Salzberg, Hadar K Shimshon, Andrew Draheim, Mark Spivak, David Shifteh

Int J Mol Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer.
Tzuriel Sapir, David Shifteh, Moshe Pahmer, Sanjay Goel, Radhashree Maitra

Mol Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein Arginine Methyltransferase 5 as a Therapeutic Target for Mutated Colorectal Cancer.
David Shifteh, Tzuriel Sapir, Moshe Pahmer, Adam Haimowitz, Sanjay Goel

Cancers (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis